Top

Current Cardiology Reports

Published in:

27-09-2023 | Hypertension | Hypertension (DS Geller and DL Cohen, Section Editors)

New Potential Treatments for Resistant Hypertension

Authors: Arun Janakiraman, Debbie L. Cohen

Published in: Current Cardiology Reports | Issue 11/2023

Abstract

Purpose of Review

To provide an update and review approaches to the treatment of resistant hypertension (RH) with a focus on emerging potential therapies.

Recent Findings

Resistant hypertension is defined as a blood pressure that remains elevated above a patient’s individualized target despite the concurrent use of 3 antihypertensive agents of different classes including a diuretic or use of 4 or more antihypertensive agents. Patients with RH have an increased risk of adverse cardiovascular and renal outcomes. Most RH is attributed to apparent RH and is not true RH. True RH is a diagnosis of exclusion after apparent RH has been excluded. Treatment of RH is challenging, and blood pressure goal is often difficult to achieve. Currently several new therapies have emerged with forthcoming data that provide promise for improved blood pressure control in those with resistant hypertension.

Summary

Once RH has been diagnosed, patients should be on standardized therapy that includes agents from three different classes including a diuretic with addition in most cases of a mineralocorticoid as a fourth line agent. There are newer agents in development currently being studied in clinical trials including dual endothelin receptor antagonists and aldosterone synthase inhibitors that appear to be efficacious. Other approved medications including SGLT2 inhibitors and non-steroidal mineralocorticoids such as finerenone also need to be incorporated into treatment paradigms. Renal denervation with catheter based devices is another potential promising treatment option in this population.

Centers for Disease Control and Prevention. Hypertension cascade: hypertension prevalence, treatment and control estimates among U.S. adults aged 18 years and older applying the criteria from the American College of Cardiology and American Heart Association’s 2017 Hypertension Guideline—NHANES 2015–2018. Atlanta, GA: U.S. Department of Health and Human Services; 2021.

Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–90. https://doi.org/10.1161/HYP.0000000000000084.CrossRefPubMed

Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42. https://doi.org/10.1161/CIRCULATIONAHA.111.068064.CrossRefPubMedPubMedCentral

Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension–its identification and epidemiology [published correction appears in Nat Rev Nephrol. 2013 Sep;9(9):492]. Nat Rev Nephrol. 2013;9(1):51–8. https://doi.org/10.1038/nrneph.2012.260.CrossRefPubMed

Cohen JB. Hypertension in obesity and the impact of weight loss. Curr Cardiol Rep. 2017;19:98. https://doi.org/10.1007/s11886-017-0912-4.CrossRefPubMedPubMedCentral

Fay KS, Cohen DL. Resistant hypertension in people with CKD: a review. Am J Kidney Dis. 2021;77(1):110–21. https://doi.org/10.1053/j.ajkd.2020.04.017.CrossRefPubMed

Brambilla G, Bombelli M, Seravalle G, et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens. 2013;31(10):2018–24. https://doi.org/10.1097/HJH.0b013e328363823f.CrossRefPubMed

Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E. Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension. 2014;64(3):501–7. https://doi.org/10.1161/HYPERTENSIONAHA.114.03718.CrossRefPubMed

Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55(3):441–51. https://doi.org/10.1053/j.ajkd.2009.09.014.CrossRefPubMed

10.

Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168(21):2340–6. https://doi.org/10.1001/archinte.168.21.2340.CrossRefPubMed

11.

Aronow WS. Lifestyle measures for treating hypertension. Arch Med Sci. 2017;13(5):1241–3. https://doi.org/10.5114/aoms.2017.68650.CrossRefPubMedPubMedCentral

12.

Huang L, Trieu K, Yoshimura S, Neal B, Woodward M, Campbell NRC, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ. 2020;368:m315. https://doi.org/10.1136/bmj.m315.CrossRefPubMedPubMedCentral

13.

Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475–81. https://doi.org/10.1161/HYPERTENSIONAHA.109.131235.CrossRefPubMed

14.

Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res. 2019;124(7):1061–70. https://doi.org/10.1161/CIRCRESAHA.118.312156.CrossRefPubMedPubMedCentral

15.

Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68. https://doi.org/10.1016/S0140-6736(15)00257-3.CrossRefPubMedPubMedCentral

16.

Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies [published correction appears in Lancet Diabetes Endocrinol. 2018 Aug;6(8):e16]. Lancet Diabetes Endocrinol. 2018;6(6):464–75. https://doi.org/10.1016/S2213-8587(18)30071-8.CrossRefPubMedPubMedCentral

17.

Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507–19. https://doi.org/10.1056/NEJMoa2110730.CrossRefPubMedPubMedCentral

18.

Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med. 2022;387(26):2401–10. https://doi.org/10.1056/NEJMoa2212270.CrossRefPubMed

19.

• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29. https://doi.org/10.1056/NEJMoa2025845. Findings from this study reveal lower risks of CKD progression and cardiovascular events than placebo.CrossRefPubMed

20.

•• Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–63. https://doi.org/10.1056/NEJMoa2110956. Results showed that when added to standard thereapy, finerenone was superior to placebo in cardiovascular outcomes.

21.

Parfianowicz D, Shah S, Nguyen C, et al. Finerenone: a new era for mineralocorticoid receptor antagonism and cardiorenal protection. Curr Probl Cardiol. 2022;47(12):101386. https://doi.org/10.1016/j.cpcardiol.2022.101386.CrossRefPubMed

22.

Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study [published correction appears in Clin Kidney J. 2019 Feb 11;13(4):722]. Clin Kidney J. 2018;11(6):749–61. https://doi.org/10.1093/ckj/sfy090.CrossRefPubMedPubMedCentral

23.

Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42:693–700. https://doi.org/10.2337/dc18-2207.CrossRefPubMedPubMedCentral

24.

Mancia G, Cannon CP, Tikkanen I, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016;68(6):1355–64. https://doi.org/10.1161/HYPERTENSIONAHA.116.07703.CrossRefPubMed

25.

Kario K, Okada K, Kato M, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study [published online ahead of print, 2018 Nov 29]. Circulation. 2018;139(18):2089–97. https://doi.org/10.1161/CIRCULATIONAHA.118.037076.CrossRefPubMedPubMedCentral

26.

Ferdinand KC, Izzo JL, Lee J, et al. Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension. Circulation. 2019;139(18):2098–109. https://doi.org/10.1161/CIRCULATIONAHA.118.036568.CrossRefPubMed

27.

Bogman K, Schwab D, Delporte ML, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69(1):189–96. https://doi.org/10.1161/HYPERTENSIONAHA.116.07716.CrossRefPubMed

28.

• Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395–405. https://doi.org/10.1056/NEJMoa2213169. The BP lowering effect across all doses when added to standard therapy was significant.CrossRefPubMed

29.

• Bhatt DL. HALO: results from a phase 2, double-blind, placebo-controlled trial evaluating the efficacy and safety of baxdrostat in patients with uncontrolled hypertension. Presented at: ACC/WCC 2023. March 4, 2023. New Orleans, LA. Negative study in which the placebo group had a significant reduction in BP.

30.

Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–5. https://doi.org/10.1038/332411a0.CrossRefPubMed

31.

Prasad VS, Palaniswamy C, Frishman WH. Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol Rev. 2009;17(4):181–91. https://doi.org/10.1097/CRD.0b013e3181aa8f4a.CrossRefPubMed

32.

Kuntz M, Leiva-Juarez MM, Luthra S. Systematic review of randomized controlled trials of endothelin receptor antagonists for pulmonary arterial hypertension. Lung. 2016;194(5):723–32. https://doi.org/10.1007/s00408-016-9928-6.CrossRefPubMed

33.

Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9699):1423–31. https://doi.org/10.1016/S0140-6736(09)61500-2.CrossRefPubMed

34.

Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):527–35. https://doi.org/10.1681/ASN.2009060593.CrossRefPubMedPubMedCentral

35.

• Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial [published correction appears in Lancet. 2023 Jan 28;401(10373):268]. Lancet. 2022;400(10367):1927–37. https://doi.org/10.1016/S0140-6736(22)02034-7. In addition to significant reduction in BP, this study showed reduction in proteinuria for patients.

36.

Bradford JR. The innervation of the renal blood vessels. J Physiol. 1889;10(5):358.CrossRefPubMedPubMedCentral

37.

Peet MM, Woods WW, Braden S. The surgical treatment of hypertension: results in 350 consecutive cases treated by bilateral supradiaphragmatic splanchnicectomy and lower dorsal sympathetic ganglionectomy clinical lecture at New York session. J Am Med Assoc. 1940;115(22):1875–85.CrossRef

38.

Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. https://doi.org/10.1016/S0140-6736(10)62039-9.CrossRef

39.

Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62(3):526–32. https://doi.org/10.1161/HYPERTENSIONAHA.113.01452.CrossRefPubMed

40.

Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022;400(10361):1405–16. https://doi.org/10.1016/S0140-6736(22)01787-1.CrossRefPubMed

41.

Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–51. https://doi.org/10.1016/S0140-6736(20)30554-7.CrossRefPubMed

42.

Azizi M, Daemen J, Lobo MD, et al. 12-month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation [published correction appears in JACC Cardiovasc Interv. 2021 Mar 8;14(5):593]. JACC Cardiovasc Interv. 2020;13(24):2922–33. https://doi.org/10.1016/j.jcin.2020.09.054.CrossRefPubMed

43.

Kario K, Mahfoud F, Kandzari DE, et al. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res. 2023;46(1):280–8. https://doi.org/10.1038/s41440-022-01042-8.CrossRefPubMed

44.

Azizi M, Saxena M, Wang Y, et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial [published correction appears in JAMA. 2023 Jun 13;329(22):1989]. JAMA. 2023;329(8):651–61. https://doi.org/10.1001/jama.2023.0713.CrossRefPubMedPubMedCentral

45.

Azizi M, Mahfoud F, Weber MA, et al. Effects of renal denervation vs sham in resistant hypertension after medication escalation: prespecified analysis at 6 months of the RADIANCE-HTN TRIO randomized clinical trial. JAMA Cardiol. 2022;7(12):1244–52. https://doi.org/10.1001/jamacardio.2022.3904.CrossRefPubMedPubMedCentral

46.

Fengler K. Renal denervation for resistant hypertension: a concise update on treatment options and the latest clinical evidence. Cardiol Ther. 2022;11(3):385–92. https://doi.org/10.1007/s40119-022-00275-5.CrossRefPubMedPubMedCentral

47.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115. https://doi.org/10.1161/HYP.0000000000000065. Epub 2017 Nov 13. Erratum in: Hypertension. 2018 Jun;71(6):e140-e144. PMID: 29133356.

Title: New Potential Treatments for Resistant Hypertension
Authors: Arun Janakiraman
Debbie L. Cohen
Publication date: 27-09-2023
Publisher: Springer US
Keywords: Hypertension
Finerenone
Cardiovascular Disease in General Practice
Cardiology
Hypertension
Neurotomy
Diuretics
Chlorthalidone
Published in: Current Cardiology Reports / Issue 11/2023
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01966-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

New Potential Treatments for Resistant Hypertension

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 11/2023

Novel Approaches to the Failing Congenital Heart

The Evolving Paradigm of Revascularization in Ischemic Cardiomyopathy: from Recovery of Systolic Function to Protection Against Future Ischemic Events

Long-Term Remote vs. Conventional Monitoring of Pacemakers: Systematic Review and Meta-Analysis of Randomized Controlled Trials

How much resistance exercise is needed to improve CV health?

TAVR in TAVR: Where Are We in 2023 for Management of Failed TAVR Valves?

Artificial Intelligence and Machine Learning Applications in Sudden Cardiac Arrest Prediction and Management: A Comprehensive Review